Join the Nivolumab group to help and get support from people like you.
Nivolumab News
Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
THURSDAY, June 12, 2025 – For patients with metastatic melanoma, mitochondrial (MT) haplogroup T (HG-T) is associated with resistance to an anti-programmed cell death protein-1-based immune...
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) April 11, 2025 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (...
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
PRINCETON, N.J.--(BUSINESS WIRE)-- Apr 08, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (i...
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
THURSDAY, Feb. 6, 2025 – For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding...
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...
Entinostat + Nivolumab Yields Durable Results in Some Pancreatic Cancer Patients
FRIDAY, Nov. 22, 2024 – Combination treatment with entinostat and nivolumab results in durable responses in a small subset of patients with advanced pancreatic ductal adenocarcinoma (PDA), according...
Science Reveals Why Cancer Immunotherapies Can Sometimes Harm the Heart
FRIDAY, Nov. 8, 2024 – Researchers think they’ve figured out why cancer treatments that harness a person’s immune system to fight a tumor can cause heart damage in rare instances. Further, what the...
Monthly News Roundup - October 2024
FDA Approves AbbVie’s Vyalev to Treat Advanced Parkinson Disease In October, the US Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa) for the treatment of motor f...
New Combo Drug Therapy Halves Death Risk From Advanced Hodgkin Lymphoma
WEDNESDAY, Oct. 16, 2024 – Jenna Cottrell is a young sports reporter working for a TV station in the Rochester, N.Y., area. She's also a survivor of advanced Hodgkin lymphoma, who first got...
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
WEDNESDAY, Oct. 16, 2024 – For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields longer progression-free survival (PFS) than...
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE) Oct 03, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo ® (nivolumab) for the treatment of ...
Long-Term Survival Benefit Seen for Nivolumab in Advanced Melanoma
THURSDAY, Sept. 19, 2024 – For patients with advanced melanoma, there is a survival benefit for nivolumab plus ipilimumab and for nivolumab monotherapy compared with ipilimumab monotherapy,...
Perioperative Nivolumab Beneficial for Resectable NSCLC
THURSDAY, Sept. 12, 2024 – For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free survival (EFS) benefit compared with neoadjuvant...
U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) Mar 07, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with ...
U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1 CheckMate -76K marks the fifth Opdivo-based...
Further information
Related condition support groups
Hepatocellular Carcinoma, Colorectal Cancer, Gastric Cancer, Hodgkin's Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma